Literature DB >> 26358762

Is heart rate a risk marker in patients with chronic heart failure and concomitant atrial fibrillation? Results from the MAGGIC meta-analysis.

Joanne Simpson1, Davide Castagno2, Rob N Doughty3, Katrina K Poppe3, Nikki Earle3, Iain Squire4, Mark Richards5, Bert Andersson6, Justin A Ezekowitz7, Michel Komajda8, Mark C Petrie9, Finlay A McAlister10, Greg D Gamble3, Gillian A Whalley11, John J V McMurray1.   

Abstract

AIM: To investigate the relationship between heart rate and survival in patients with heart failure (HF) and coexisting atrial fibrillation (AF). METHODS AND
RESULTS: Patients with AF included in the Meta-analysis Global Group in Chronic Heart Failure (MAGGIC) meta-analysis were the main focus of this analysis (3259 patients from 17 studies). The outcome was all-cause mortality at 3 years. Heart rate was analysed as a categorical (tertiles; T1 ≤77 b.p.m., T2 78-98 b.p.m., T3 ≥98 b.p.m.) and continuous variable. Cox proportional hazard models were used to compare the risk of all-cause death between tertiles of baseline heart rate. Patients in the highest tertile were more often female, less likely to have an ischaemic aetiology or diabetes, had a lower ejection fraction but higher blood pressure and New York Heart Association (NYHA) class. Higher heart rate was associated with higher mortality in patients with sinus rhythm (SR) but not in those in AF. In patients with heart failure and reduced ejection fraction (HF-REF) and AF, death rates per 100 patient years were lowest in the highest heart rate tertile (T1 18.9 vs. T3 15.9) but this difference was not statistically significant (P = 0.10). In patients with heart failure and preserved ejection fraction (HF-PEF), death rates per 100 patient years were highest in the highest heart rate tertile (T1 14.6 vs. T3 16.0, P = 0.014). However, after adjustment for other important prognostic variables, higher heart rate was no longer associated with higher mortality in HF-PEF (or HF-REF).
CONCLUSIONS: In this meta-analysis of patients with HF, heart rate does not have the same prognostic significance in patients in AF as it does in those in SR, irrespective of ejection fraction or treatment with beta-blocker.
© 2015 The Authors European Journal of Heart Failure © 2015 European Society of Cardiology.

Entities:  

Keywords:  Atrial fibrillation; Heart failure; Heart rate; Preserved ejection fraction; Prognosis

Mesh:

Substances:

Year:  2015        PMID: 26358762     DOI: 10.1002/ejhf.346

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  9 in total

1.  The effect of beta-blockers on mortality in patients with heart failure and atrial fibrillation: A meta-analysis of observational cohort and randomized controlled studies.

Authors:  Gai-Gai Ma; Quan Fang; Feng-Xia Wang
Journal:  Cardiol J       Date:  2018-07-16       Impact factor: 2.737

2.  β-Blockers and 1-Year Postdischarge Mortality for Heart Failure and Reduced Ejection Fraction and Slow Discharge Heart Rate.

Authors:  Jin Joo Park; Hyun-Ah Park; Hyun-Jai Cho; Hae-Young Lee; Kye Hun Kim; Byung-Su Yoo; Seok-Min Kang; Sang Hong Baek; Eun-Seok Jeon; Jae-Joong Kim; Myeong-Chan Cho; Shung Chull Chae; Byung-Hee Oh; Dong-Ju Choi
Journal:  J Am Heart Assoc       Date:  2019-02-19       Impact factor: 5.501

3.  Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Authors:  Ify R Mordi; Bernadet T Santema; Mariëlle Kloosterman; Anna-Maria Choy; Michiel Rienstra; Isabelle van Gelder; Stefan D Anker; John G Cleland; Kenneth Dickstein; Gerasimos Filippatos; Pim van der Harst; Hans L Hillege; Marco Metra; Leong L Ng; Wouter Ouwerkerk; Piotr Ponikowski; Nilesh J Samani; Dirk J van Veldhuisen; Aeilko H Zwinderman; Faiez Zannad; Adriaan A Voors; Chim C Lang
Journal:  Clin Res Cardiol       Date:  2019-01-04       Impact factor: 5.460

Review 4.  Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.

Authors:  Diana-Carina Iovanovici; Simona Gabriela Bungau; Cosmin Mihai Vesa; Madalina Moisi; Elena Emilia Babes; Delia Mirela Tit; Tunde Horvath; Tapan Behl; Marius Rus
Journal:  Int J Mol Sci       Date:  2022-09-26       Impact factor: 6.208

Review 5.  Therapeutic approaches in heart failure with preserved ejection fraction: past, present, and future.

Authors:  Jan Wintrich; Ingrid Kindermann; Christian Ukena; Simina Selejan; Christian Werner; Christoph Maack; Ulrich Laufs; Carsten Tschöpe; Stefan D Anker; Carolyn S P Lam; Adriaan A Voors; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2020-03-31       Impact factor: 5.460

6.  Beta-blocker Therapy at Discharge in Patients with Acute Heart Failure and Atrial Fibrillation.

Authors:  Min Soo Ahn; Byung Su Yoo; Jung Woo Son; Min Heui Yu; Dae Ryong Kang; Hae Young Lee; Eun Seok Jeon; Jae Joong Kim; Shung Chull Chae; Sang Hong Baek; Seok Min Kang; Dong Ju Choi; Kye Hun Kim; Myeong Chan Cho; Seong Yoon Kim
Journal:  J Korean Med Sci       Date:  2020-08-24       Impact factor: 2.153

7.  The Effect of Ivabradine on the Human Atrial Myocardial Contractility in an In Vitro Study.

Authors:  Ryan Chaban; Katja Buschmann; Anna Krausgrill; Andres Beiras-Fernandez; Christian-Friedrich Vahl
Journal:  Cardiol Res Pract       Date:  2019-10-30       Impact factor: 1.866

8.  Guideline-directed therapy at discharge in patients with heart failure and atrial fibrillation.

Authors:  Min-Soo Ahn; Byung Su Yoo; Junghan Yoon; Seung-Hwan Lee; Jang Young Kim; Sung Gyun Ahn; Young Jin Youn; Jun-Won Lee; Jung-Woo Son; Hye Sim Kim; Dae Ryong Kang; Hyun-Jai Cho; Hae-Young Lee; Eun Seok Jeon; Seok-Min Kang; Dong-Ju Choi; Myeong-Chan Cho
Journal:  Heart       Date:  2019-09-06       Impact factor: 5.994

Review 9.  Myocardial Tissue Characterization in Heart Failure with Preserved Ejection Fraction: From Histopathology and Cardiac Magnetic Resonance Findings to Therapeutic Targets.

Authors:  Paolo Severino; Andrea D'Amato; Silvia Prosperi; Francesca Fanisio; Lucia Ilaria Birtolo; Bettina Costi; Lucrezia Netti; Cristina Chimenti; Carlo Lavalle; Viviana Maestrini; Massimo Mancone; Francesco Fedele
Journal:  Int J Mol Sci       Date:  2021-07-17       Impact factor: 6.208

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.